Detection Technology Plc financial statements review January-December 2025

Detection Technology reported FY2025 net sales of EUR 101.0m, down 6.0% year-on-year, with Q4 sales EUR 29.7m (-6.1%). EBITA fell to EUR 9.3m (9.2% margin) vs EUR 14.9m a year earlier and EBITA excl. NRI was EUR 9.6m; diluted EPS declined to EUR 0.44 from EUR 0.76 and the Board proposes a reduced dividend of EUR 0.30 per share. Management flagged headwinds including exchange-rate effects, regulatory delays, new U.S. import tariffs and China price competition but reiterated a strengthened outlook, forecasting double-digit net sales growth in Q1/H1 2026 and targeting ≥10% annual sales growth and a 15% EBITA margin in the medium term, supported by product launches and expansion (new India factory).

Analysis

Market structure: Detection Technology (DETEC) is shifting from cyclical security demand toward medical and industrial TFT markets (TFT sales +60% YoY in China) which should increase its share in higher-margin medical imaging over 12–24 months. Near-term top-line slipped -6% to EUR101m and EBITA margin compressed to 9.2% (from 13.9%), but net cash ~EUR20.5m and product wins (GE HealthCare Supplier of the Year) preserve pricing power in strategic OEM channels. Supply-side risks (US tariffs, component shortages) increase lead-time and favor vertically integrated suppliers with global footprint (DETEC has sites in FI/CN/IN/US). Cross-asset: weakness in small-cap industrial equities likely to widen credit spreads and raise equity implied volatility; EUR/FX volatility matters as FX hurt 2025 results.

Risk assessment: Tail risks include sudden US import tariffs or China price wars that could knock annual sales below -10% (probability ~10% over 12 months) and prolong aviation-CT regulatory delays restarting cash flows; product lifecycle obsolescence (analog end-of-life) can cause inventory write-offs. Short-term (days-weeks) catalyst risk centers on Q1 sales cadence and tariff headlines; medium-term (3–12 months) depends on China TFT momentum and India factory ramp; long-term hinges on successful DT2030 software+hardware monetization to hit 15% EBITA. Hidden dependencies: large OEM inventory policies and a few key customers concentration; unwind of buffers can produce lumpy revenue.

Trade implications: Constructive event trade: take a modest long in DETEC ahead of Q1/H1 2026 guidance to capture expected double-digit growth, but size with binary risk controls (scale in 50% now, add on confirming sales). Use options to convert this into defined-risk exposure (six-month call-debit-spread) if liquidity allows. Rotate 2–4% from pure security-scanning small caps into medical-imaging names (e.g., GE HealthCare, GEHC) to favor durable OEM relationships; hedge FX exposure if entry priced in EUR.

Contrarian angles: Consensus focuses on weak security sales; market underestimates TFT-driven upside—the 60% TFT growth in China can re-rate margins if sustained >30% YoY for two quarters. The stock may be over-penalized for transient regulatory delays and inventory cycles; a confirmed Q1 beat (>+10% y/y sales at constant FX and EBITA margin >12%) should trigger rapid multiple expansion. Unintended consequence: aggressive shorting of DETEC could backfire if GEHC and other OEM endorsements accelerate orders; watch OEM order confirmations as early signal.

Key Decisions for Investors

• Establish a 2–3% long position in Detection Technology (DETEC) within 1–4 weeks, size half now and add to reach target only if Q1 2026 net sales > +10% y/y at constant FX or EBITA margin recovers to >12%; set hard stop-loss at -20% and target partial take-profit at +40% within 6–12 months.
• If liquid, buy a six-month DETEC call-debit-spread (buy near-the-money call, sell +25–35% OTM call) to cap premium—risk limited, target price move ≥+15% ahead of Q1/H1 catalysts; if no options, use a 1–2% equity position instead.
• Rotate 2–4% portfolio weight from pure-security X-ray small-caps into medical-imaging OEM exposure: go long GE HealthCare (GEHC) 1–2% for 3–9 months to capture durable OEM demand and mitigate single-vendor risk; rebalance if DETEC confirms >2 sequential quarters of margin recovery.
• Avoid initiating shorts on DETEC; instead, selectively hedge exposure to small European industrial imaging peers with 3–6 month put options if tariff headlines escalate — trigger hedge if new US tariffs announced or if DETEC reports sequential Q1 sales decline >5% at constant FX.